Neurocrine Biosciences (NBIX) reported $805.5 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 28.3%. EPS of $1.88 for the same period compares to $1.00 a year ago.
The reported revenue represents a surprise of +2.89% over the Zacks Consensus Estimate of $782.91 million. With the consensus EPS estimate being $2.25, the EPS surprise was -16.55%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net- INGREZZA: $657.5 million versus the nine-analyst average estimate of $661.61 million. The reported number represents a year-over-year change of +6.9%.
- Revenues- Product sales, net: $798.3 million versus $788.24 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +28.5% change.
- Revenues- Product sales, net- CRENESSITY: $135.4 million versus the nine-analyst average estimate of $120.56 million.
- Revenues- Collaboration revenue: $7.2 million versus the eight-analyst average estimate of $6.46 million. The reported number represents a year-over-year change of +10.8%.
- Revenues- Product sales, net- Other: $5.4 million compared to the $4.1 million average estimate based on three analysts. The reported number represents a change of -11.5% year over year.
View all Key Company Metrics for Neurocrine here>>>
Shares of Neurocrine have returned +4.1% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
